Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Brenmiller Reports 2024 Financial Results and Pipeline of Commercial Opportunities Reaches Over Half-Billion Dollars
-
Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
-
ReTo Eco-Solutions, Inc. Announces Share Combination
-
NYSE American to Commence Delisting Proceedings Against Zomedica Corp. (ZOM)
-
Potbelly Launches Large Area Developer Incentive Program for Multi-Unit Franchisees
-
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
-
Sage Therapeutics Announces R&D Leadership Transition
-
FTK Awarded $13.7 MM Colorado Project
-
O-I Glass to Host 2025 Investor Day
-
Greystone Housing Impact Investors Files Form 10-K and Issues Investor Schedule K-1s
-
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
-
TXO Partners Declares a Fourth Quarter 2024 Distribution of $0.61 on Common Units; Provides 2025 Distribution Outlook and Files Annual Report on Form 10-K
-
EarthLabs Expeditions, The Adventure Continues with Rua Gold
-
Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results
-
CrowdStrike Reports Fourth Quarter and Fiscal Year 2025 Financial Results
-
Custom Truck One Source, Inc. Reports Fourth Quarter and Full-Year 2024 Results
-
AeroVironment Announces Fiscal 2025 Third Quarter Results
-
Flexsteel Industries, Inc. Announces Quarterly Dividend
-
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Coca-Cola Consolidated Board of Directors Approves 10 for 1 Stock Split
-
Sprott Focus Trust, Inc. (Nasdaq-FUND) Declares First Quarter Common Stock Distribution of $0.1305 Per Share
-
FCP EXPANDS FLORIDA FOOTPRINT WITH ACQUISITION OF 400-UNIT ARIUM SUNRISE IN PARTNERSHIP WITH BMC INVESTMENTS AND THE RMR GROUP
-
Patients Want to Advocate For Themselves - Here's How They Can
-
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Casa Herrera’s Lean Transformation: How Partnering with CMTC Helped to Improve Processes and Reduce Costs
-
Owlet Announces Fourth Quarter and Full Year 2024 Results
-
Supergut Announces New Funding and Expands Leadership
-
Stem’s PowerTrack™ Standard on Summit Ridge Energy’s 514 MW Commercial Solar Portfolio
-
Teknova Reports Fourth Quarter and Full Year 2024 Financial Results
-
Eos Energy Enterprises Meets 2024 Revised Revenue Guidance and Reports Fourth Quarter & Full-Year 2024 Financial Results; Reaffirms 2025 Revenue Guidance
-
Sanuwave Health to Uplist to the Nasdaq Global Market
-
Gulf Island Reports Fourth Quarter and Full Year 2024 Results
-
Enstar Completes Previously Announced Transaction with Atrium Syndicate 609
-
PennantPark Investment Corporation Announces Monthly Distribution of $0.08 per Share
-
Orion Group Holdings Reports Fourth Quarter and Full Year 2024 Results
-
Arvinas to Participate in Upcoming Investor Conferences
-
Cricut, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
-
Eos Energy Enterprises Meets 2024 Revised Revenue Guidance and Reports Fourth Quarter & Full-Year 2024 Financial Results; Reaffirms 2025 Revenue Guidance
-
Dave & Buster’s Announces Appointment of Cory Hatton to Head of Entertainment Finance, Investor Relations & Treasurer
-
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
-
Stem Announces Fourth Quarter and Full Year 2024 Results
-
Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
-
Lincoln National Corporation Elects Jim Morris to Serve on the Board of Directors
-
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
-
Box Reports Fourth Quarter and Fiscal 2025 Financial Results
-
ChargePoint Reports Fourth Quarter and Full Fiscal Year 2025 Financial Results
-
Columbus McKinnon to Present at the J.P. Morgan 2025 Industrials Conference
-
Lam Research Corporation Announces Participation at Upcoming Conference
-
Strong Proof-of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL’36), a Novel Once-Daily Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease
-
Credo Reports Third Quarter of Fiscal Year 2025 Financial Results
